<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="28072684MD-D-16-04055 doi: 10.1097/MD.000000000000532105321 : 4500: Research ArticleObservational Study Assessment of" exact="hepatocellular carcinoma" post="risk based on peg-interferon plus ribavirin treatment experience in"/>
 <result pre="doi: 10.1097/MD.000000000000532105321 : 4500: Research ArticleObservational Study Assessment of hepatocellular" exact="carcinoma" post="risk based on peg-interferon plus ribavirin treatment experience in"/>
 <result pre="this new era of highly effective oral antiviral drugs for" exact="chronic hepatitis" post="C virus (HCV), indications for antiviral treatment may be"/>
 <result pre="new era of highly effective oral antiviral drugs for chronic" exact="hepatitis" post="C virus (HCV), indications for antiviral treatment may be"/>
 <result pre="suitable candidates for peg-interferon plus ribavirin (PEG-IFN/RBV) treatment by evaluating" exact="hepatocellular carcinoma" post="(HCC) risk in patients with chronic HCV treated or"/>
 <result pre="candidates for peg-interferon plus ribavirin (PEG-IFN/RBV) treatment by evaluating hepatocellular" exact="carcinoma" post="(HCC) risk in patients with chronic HCV treated or"/>
 <result pre="treatment by evaluating hepatocellular carcinoma (HCC) risk in patients with" exact="chronic" post="HCV treated or not with PEG-IFN/RBV. This large-scale retrospective"/>
 <result pre="This large-scale retrospective study was conducted on 1176 patients with" exact="chronic" post="HCV without a history of HCC (treatment group [n = 489]"/>
 <result pre="SVR (+) (1.1%) and SVR (−) (8.6%) subgroups were significantly" exact="lower" post="than in the no-treatment group (13.5%) (P &amp;lt; 0.01 and P &amp;lt; 0.01,"/>
 <result pre="(P &amp;lt; 0.01 and P &amp;lt; 0.01, respectively). In all study subjects, presence of" exact="cirrhosis" post="(hazard ratio [HR], 9.92, P &amp;lt; 0.01), age (HR 1.03, P &amp;lt; 0.01),"/>
 <result pre="In the no-treatment group, age, male, and the presence of" exact="cirrhosis" post="were independent predictors for HCC development. HCC risk increased"/>
 <result pre="predictors for HCC development. HCC risk increased in patients with" exact="chronic" post="HCV with older age, cirrhosis, SVR (−) after PEG-IFN/RBV"/>
 <result pre="drugs needs to be considered in these patients. Keywords age" exact="chronic hepatitis" post="C hepatocellular carcinoma liver cirrhosis sustained virologic response 1"/>
 <result pre="needs to be considered in these patients. Keywords age chronic" exact="hepatitis" post="C hepatocellular carcinoma liver cirrhosis sustained virologic response 1"/>
 <result pre="be considered in these patients. Keywords age chronic hepatitis C" exact="hepatocellular carcinoma" post="liver cirrhosis sustained virologic response 1 Introduction Hepatitis C"/>
 <result pre="considered in these patients. Keywords age chronic hepatitis C hepatocellular" exact="carcinoma" post="liver cirrhosis sustained virologic response 1 Introduction Hepatitis C"/>
 <result pre="in these patients. Keywords age chronic hepatitis C hepatocellular carcinoma" exact="liver cirrhosis" post="sustained virologic response 1 Introduction Hepatitis C virus (HCV)"/>
 <result pre="these patients. Keywords age chronic hepatitis C hepatocellular carcinoma liver" exact="cirrhosis" post="sustained virologic response 1 Introduction Hepatitis C virus (HCV)"/>
 <result pre="C hepatocellular carcinoma liver cirrhosis sustained virologic response 1 Introduction" exact="Hepatitis" post="C virus (HCV) has infected about 180 million population"/>
 <result pre="about 180 million population worldwide and is the major cause" exact="of liver" post="cirrhosis (LC) and hepatocellular carcinoma (HCC).[1,2] Since these diseases"/>
 <result pre="180 million population worldwide and is the major cause of" exact="liver cirrhosis" post="(LC) and hepatocellular carcinoma (HCC).[1,2] Since these diseases are"/>
 <result pre="million population worldwide and is the major cause of liver" exact="cirrhosis" post="(LC) and hepatocellular carcinoma (HCC).[1,2] Since these diseases are"/>
 <result pre="and is the major cause of liver cirrhosis (LC) and" exact="hepatocellular carcinoma" post="(HCC).[1,2] Since these diseases are associated with high mortality"/>
 <result pre="is the major cause of liver cirrhosis (LC) and hepatocellular" exact="carcinoma" post="(HCC).[1,2] Since these diseases are associated with high mortality"/>
 <result pre="diseases are associated with high mortality in the presence of" exact="chronic" post="HCV (CHC), antiviral therapy for HCV infection could theoretically"/>
 <result pre="the presence of chronic HCV (CHC), antiviral therapy for HCV" exact="infection" post="could theoretically improve prognosis by preventing the development of"/>
 <result pre="therapy reduces the risk of HCC development, the majority were" exact="limited" post="due to use of a conventional IFN regimen.[10–15] After"/>
 <result pre="long-term outcomes or HCC development.[16–21] However, unfortunately, these studies were" exact="limited" post="to bridging fibrosis or patients with LC[18,20,21] and did"/>
 <result pre="daclatasvir/asunaprevir, were recently approved with much higher SVR rates and" exact="lower" post="adverse event rates than PEG-IFN/RBV.[7–9] Given that SVR rate"/>
 <result pre="anti-HCV drugs. 2 Patients and methods 2.1 Study population A" exact="total" post="of 2578 patients registered at our institution between January"/>
 <result pre="were initially positive for HCV antibody and had no other" exact="chronic" post="liver disease, such as hepatitis B virus (HBV) infection,"/>
 <result pre="initially positive for HCV antibody and had no other chronic" exact="liver disease," post="such as hepatitis B virus (HBV) infection, alcoholic liver"/>
 <result pre="antibody and had no other chronic liver disease, such as" exact="hepatitis" post="B virus (HBV) infection, alcoholic liver disease, autoimmune hepatitis,"/>
 <result pre="chronic liver disease, such as hepatitis B virus (HBV) infection," exact="alcoholic" post="liver disease, autoimmune hepatitis, primary biliary cirrhosis, or Wilson"/>
 <result pre="liver disease, such as hepatitis B virus (HBV) infection, alcoholic" exact="liver disease," post="autoimmune hepatitis, primary biliary cirrhosis, or Wilson disease (Fig."/>
 <result pre="such as hepatitis B virus (HBV) infection, alcoholic liver disease," exact="autoimmune" post="hepatitis, primary biliary cirrhosis, or Wilson disease (Fig. 1)."/>
 <result pre="hepatitis B virus (HBV) infection, alcoholic liver disease, autoimmune hepatitis," exact="primary biliary cirrhosis," post="or Wilson disease (Fig. 1). Anti-HCV and HCV RNA"/>
 <result pre="infection, alcoholic liver disease, autoimmune hepatitis, primary biliary cirrhosis, or" exact="Wilson disease" post="(Fig. 1). Anti-HCV and HCV RNA levels were positive"/>
 <result pre="alcoholic liver disease, autoimmune hepatitis, primary biliary cirrhosis, or Wilson" exact="disease" post="(Fig. 1). Anti-HCV and HCV RNA levels were positive"/>
 <result pre="database records were retrospectively analyzed. Figure 1 Study subjects. A" exact="total" post="of 1176 patients were enrolled in the present study."/>
 <result pre="The following clinical data were obtained at diagnosis of CHC" exact="infection" post="in no-treatment group and at time of antiviral therapy"/>
 <result pre="treatment group; age (year), gender, body mass index (BMI, kg/m2)," exact="complete" post="blood count, serum alanine aminotransferase (ALT, IU/L) level, prothrombin"/>
 <result pre="serum albumin or bilirubin, serum alpha-fetoprotein (AFP) level, Child-Turcotte-Pugh classification," exact="hepatitis" post="B surface antigen or antibody, HCV RNA (IU/mL), HCV"/>
 <result pre="of LC. LC was clinically diagnosed based on evidence of" exact="portal hypertension" post="(encephalopathy, esophageal varices, ascites, or splenomegaly), low platelet count"/>
 <result pre="LC. LC was clinically diagnosed based on evidence of portal" exact="hypertension" post="(encephalopathy, esophageal varices, ascites, or splenomegaly), low platelet count"/>
 <result pre="was clinically diagnosed based on evidence of portal hypertension (encephalopathy," exact="esophageal varices," post="ascites, or splenomegaly), low platelet count (&amp;lt;100,000/mm3), or liver"/>
 <result pre="evidence of portal hypertension (encephalopathy, esophageal varices, ascites, or splenomegaly)," exact="low platelet count" post="(&amp;lt;100,000/mm3), or liver ultrasonography (USG) findings.[22,23] SVR was defined"/>
 <result pre="treatment in the treatment group and after diagnosis of CHC" exact="infection" post="in the no-treatment group and continued until date of"/>
 <result pre="or continuous variables were analyzed using the Chi-squared test, the" exact="Fisher" post="exact test, or the Student t test. Statistical differences"/>
 <result pre="Inc, Chicago, IL). 3 Results 3.1 Patient baseline characteristics A" exact="total" post="of 1176 patients were enrolled in the study (Fig."/>
 <result pre="who developed HCC (P &amp;lt; 0.01), males (P = 0.03), and the rate of" exact="cirrhosis" post="(P &amp;lt; 0.01) were significantly higher in patients who developed HCC"/>
 <result pre="during follow-up. 3.3 Cumulative HCC development in patients with CHC" exact="infection" post="HCC developed in 114 (9.7%) of the 1176 study"/>
 <result pre="SVR (+) subgroup (0%, 0%, and 1.1%, respectively) were significantly" exact="lower" post="than in the SVR (−) subgroup (3.9%, 6.4%, and"/>
 <result pre="of patients who achieved SVR on PEG-IFN/RBV therapy was significantly" exact="lower" post="than the rate of those who did not and"/>
 <result pre="greater than those with other genotypes (P = 0.09) (C). HCC =" exact="hepatocellular carcinoma," post="LC = liver cirrhosis, PEG-IFN/RBV = peg-interferon plus ribavirin,"/>
 <result pre="other genotypes (P = 0.09) (C). HCC = hepatocellular carcinoma, LC =" exact="liver cirrhosis," post="PEG-IFN/RBV = peg-interferon plus ribavirin, SVR = sustained virologic"/>
 <result pre="that of those with other genotypes (P = 0.047) (B). HCC =" exact="hepatocellular carcinoma," post="LC = liver cirrhosis. In the no-treatment group, HCC"/>
 <result pre="other genotypes (P = 0.047) (B). HCC = hepatocellular carcinoma, LC =" exact="liver cirrhosis." post="In the no-treatment group, HCC developed in 94 (13.7%)"/>
 <result pre="cumulative HCC development rates were significantly greater for male than" exact="female" post="patients (10.9%, 15.4%, and 20.0% vs 8.4%, 10.0%, and"/>
 <result pre="rate of male patients was significantly greater than that of" exact="female" post="patients (P = 0.02) (A). The cumulative HCC development rate of"/>
 <result pre="1 or another genotype were similar (P = 0.59) (C). HCC =" exact="hepatocellular carcinoma," post="LC = liver cirrhosis. 3.5 Factors predictive of HCC"/>
 <result pre="were similar (P = 0.59) (C). HCC = hepatocellular carcinoma, LC =" exact="liver cirrhosis." post="3.5 Factors predictive of HCC development in all patients"/>
 <result pre="that older age (hazard ratio [HR] 1.06, P &amp;lt; 0.01), presence of" exact="cirrhosis" post="(HR 14.89, P &amp;lt; 0.01), higher serum HCV RNA levels (HR"/>
 <result pre="analysis showed that older age (HR 1.03, P &amp;lt; 0.01), presence of" exact="cirrhosis" post="(HR 9.92, P &amp;lt; 0.01), SVR (−) (HR 7.02, P &amp;lt; 0.01), and"/>
 <result pre="3 Significant predictive factors of HCC development in patients with" exact="chronic" post="HCV infection. 3.6 Factors predictive of HCC development in"/>
 <result pre="the treatment group, older age (HR 1.05, P = 0.02), presence of" exact="cirrhosis" post="(HR 6.35, P &amp;lt; 0.01), and SVR (−) (HR 10.73, P &amp;lt; 0.01)"/>
 <result pre="(HR 1.03, P &amp;lt; 0.01), male (HR 1.68, P = 0.02), and presence of" exact="cirrhosis" post="(HR 11.64, P &amp;lt; 0.01) independently predicted HCC development (Table 4)."/>
 <result pre="in treatment-naïve CHC genotype 1 patients with treatment durations as" exact="short" post="as 12 or 24 weeks.[7,9,24] Moreover, in genotype 2"/>
 <result pre="a well-known risk factor of HCC development regardless of underlying" exact="liver disease," post="and thus, cirrhotic patients are candidates for active surveillance"/>
 <result pre="program of HCC development.[37] In addition, cirrhotic patients with HBV" exact="infection" post="have been actively treated with antiviral drugs.[38] Although the"/>
 <result pre="drugs.[38] Although the previous guideline recommended cirrhotic patients with HCV" exact="infection" post="can be treated using PEG-IFN/RBV, it is also stated"/>
 <result pre="In addition, according to current guidelines, HCV patients with decompensated" exact="cirrhosis" post="can also be treated with new DAA agents,[7–9] and"/>
 <result pre="associated with the risk of HCV-related HCC, such as, obesity," exact="diabetes mellitus," post="and insulin resistance, were not addressed in the present"/>
 <result pre="in the present study. Fourth, median follow-up duration was relatively" exact="short" post="as 31 months, and therefore, long-term follow-up data are"/>
 <result pre="CHC, an older age, a male gender, and presence of" exact="cirrhosis" post="were found to predict HCC development. In our opinion,"/>
 <result pre="= alanine aminotransferase, BMI = body mass index, CHC =" exact="chronic" post="HCV, DAA = direct-acting antiviral, HBV = hepatitis B"/>
 <result pre="CHC = chronic HCV, DAA = direct-acting antiviral, HBV =" exact="hepatitis" post="B virus, HCC = hepatocellular carcinoma, HCV = hepatitis"/>
 <result pre="= direct-acting antiviral, HBV = hepatitis B virus, HCC =" exact="hepatocellular carcinoma," post="HCV = hepatitis C virus, IFN = interferon, LC"/>
 <result pre="= hepatitis B virus, HCC = hepatocellular carcinoma, HCV =" exact="hepatitis" post="C virus, IFN = interferon, LC = liver cirrhosis,"/>
 <result pre="HCV = hepatitis C virus, IFN = interferon, LC =" exact="liver cirrhosis," post="PEG-IFN/RBV = peg-interferon plus ribavirin, SVR = sustained virologic"/>
 <result pre="to disclose. References References [1]GhanyMGStraderDBThomasDLet al.Diagnosis, management, and treatment of" exact="hepatitis" post="C: an update. Hepatology2009;49:1335–74.19330875 [2]ShepardCWFinelliLAlterMJGlobal epidemiology of hepatitis C"/>
 <result pre="treatment of hepatitis C: an update. Hepatology2009;49:1335–74.19330875 [2]ShepardCWFinelliLAlterMJGlobal epidemiology of" exact="hepatitis" post="C virus infection. Lancet Infect Dis2005;5:558–67.16122679 [3]MannsMPMcHutchisonJGGordonSCet al.Peginterferon alfa-2b"/>
 <result pre="hepatitis C: an update. Hepatology2009;49:1335–74.19330875 [2]ShepardCWFinelliLAlterMJGlobal epidemiology of hepatitis C" exact="virus infection." post="Lancet Infect Dis2005;5:558–67.16122679 [3]MannsMPMcHutchisonJGGordonSCet al.Peginterferon alfa-2b plus ribavirin compared"/>
 <result pre="compared with interferon alfa-2b plus ribavirin for initial treatment of" exact="chronic hepatitis" post="C: a randomised trial. Lancet2001;358:958–65.11583749 [4]FriedMWShiffmanMLReddyKRet al.Peginterferon alfa-2a plus"/>
 <result pre="with interferon alfa-2b plus ribavirin for initial treatment of chronic" exact="hepatitis" post="C: a randomised trial. Lancet2001;358:958–65.11583749 [4]FriedMWShiffmanMLReddyKRet al.Peginterferon alfa-2a plus"/>
 <result pre="a randomised trial. Lancet2001;358:958–65.11583749 [4]FriedMWShiffmanMLReddyKRet al.Peginterferon alfa-2a plus ribavirin for" exact="chronic hepatitis" post="C virus infection. N Engl J Med2002;347:975–82.12324553 [5]KhurooMSKhurooMSDahabSTMeta-analysis: a"/>
 <result pre="randomised trial. Lancet2001;358:958–65.11583749 [4]FriedMWShiffmanMLReddyKRet al.Peginterferon alfa-2a plus ribavirin for chronic" exact="hepatitis" post="C virus infection. N Engl J Med2002;347:975–82.12324553 [5]KhurooMSKhurooMSDahabSTMeta-analysis: a"/>
 <result pre="Lancet2001;358:958–65.11583749 [4]FriedMWShiffmanMLReddyKRet al.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C" exact="virus infection." post="N Engl J Med2002;347:975–82.12324553 [5]KhurooMSKhurooMSDahabSTMeta-analysis: a randomized trial of"/>
 <result pre="trial of peginterferon plus ribavirin for the initial treatment of" exact="chronic hepatitis" post="C genotype 4. Aliment Pharmacol Ther2004;20:931–8.15521839 [6]NguyenMHTrinhHNGarciaRet al.Higher rate"/>
 <result pre="of peginterferon plus ribavirin for the initial treatment of chronic" exact="hepatitis" post="C genotype 4. Aliment Pharmacol Ther2004;20:931–8.15521839 [6]NguyenMHTrinhHNGarciaRet al.Higher rate"/>
 <result pre="Pharmacol Ther2004;20:931–8.15521839 [6]NguyenMHTrinhHNGarciaRet al.Higher rate of sustained virologic response in" exact="chronic hepatitis" post="C genotype 6 treated with 48 weeks versus 24"/>
 <result pre="Ther2004;20:931–8.15521839 [6]NguyenMHTrinhHNGarciaRet al.Higher rate of sustained virologic response in chronic" exact="hepatitis" post="C genotype 6 treated with 48 weeks versus 24"/>
 <result pre="AASLD-IDSA recommendations for testing, managing, and treating adults infected with" exact="hepatitis" post="C virus. Hepatology2015;62:932–54.26111063 [8]collab: European Association for Study of"/>
 <result pre="Association for Study of LiverEASL clinical practice guidelines: management of" exact="hepatitis" post="C virus infection. J Hepatol2014;60:392–420.24331294 [9]collab: Korean Association for"/>
 <result pre="Study of LiverEASL clinical practice guidelines: management of hepatitis C" exact="virus infection." post="J Hepatol2014;60:392–420.24331294 [9]collab: Korean Association for the Study of"/>
 <result pre="the Study of the LiverKASL clinical practice guidelines: management of" exact="hepatitis" post="C. Clin Mol Hepatol2016;22:76–139.27044763 [10]HungCHLeeCMLuSNet al.Long-term effect of interferon"/>
 <result pre="effect of interferon alpha-2b plus ribavirin therapy on incidence of" exact="hepatocellular carcinoma" post="in patients with hepatitis C virus-related cirrhosis. J Viral"/>
 <result pre="of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular" exact="carcinoma" post="in patients with hepatitis C virus-related cirrhosis. J Viral"/>
 <result pre="ribavirin therapy on incidence of hepatocellular carcinoma in patients with" exact="hepatitis" post="C virus-related cirrhosis. J Viral Hepat2006;13:409–14.16842444 [11]BrunoSStroffoliniTColomboMet al.Sustained virological"/>
 <result pre="hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J" exact="Viral" post="Hepat2006;13:409–14.16842444 [11]BrunoSStroffoliniTColomboMet al.Sustained virological response to interferon-alpha is associated"/>
 <result pre="carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with" exact="chronic hepatitis" post="C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis"/>
 <result pre="national surveillance program of cirrhotic and noncirrhotic patients with chronic" exact="hepatitis" post="C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis"/>
 <result pre="[13]NishiguchiSKurokiTNakataniSet al.Randomised trial of effects of interferon-alpha on incidence of" exact="hepatocellular carcinoma" post="in chronic active hepatitis C with cirrhosis. Lancet1995;346:1051–5.7564784 [14]KasaharaAHayashiNMochizukiKet"/>
 <result pre="al.Randomised trial of effects of interferon-alpha on incidence of hepatocellular" exact="carcinoma" post="in chronic active hepatitis C with cirrhosis. Lancet1995;346:1051–5.7564784 [14]KasaharaAHayashiNMochizukiKet"/>
 <result pre="of effects of interferon-alpha on incidence of hepatocellular carcinoma in" exact="chronic" post="active hepatitis C with cirrhosis. Lancet1995;346:1051–5.7564784 [14]KasaharaAHayashiNMochizukiKet al.Risk factors"/>
 <result pre="of interferon-alpha on incidence of hepatocellular carcinoma in chronic active" exact="hepatitis" post="C with cirrhosis. Lancet1995;346:1051–5.7564784 [14]KasaharaAHayashiNMochizukiKet al.Risk factors for hepatocellular"/>
 <result pre="active hepatitis C with cirrhosis. Lancet1995;346:1051–5.7564784 [14]KasaharaAHayashiNMochizukiKet al.Risk factors for" exact="hepatocellular carcinoma" post="and its incidence after interferon treatment in patients with"/>
 <result pre="hepatitis C with cirrhosis. Lancet1995;346:1051–5.7564784 [14]KasaharaAHayashiNMochizukiKet al.Risk factors for hepatocellular" exact="carcinoma" post="and its incidence after interferon treatment in patients with"/>
 <result pre="carcinoma and its incidence after interferon treatment in patients with" exact="chronic hepatitis" post="C. Osaka Liver Disease Study Group. Hepatology1998;27:1394–402.9581697 [15]ToyodaHKumadaTTadaTet al.Risk"/>
 <result pre="and its incidence after interferon treatment in patients with chronic" exact="hepatitis" post="C. Osaka Liver Disease Study Group. Hepatology1998;27:1394–402.9581697 [15]ToyodaHKumadaTTadaTet al.Risk"/>
 <result pre="after interferon treatment in patients with chronic hepatitis C. Osaka" exact="Liver Disease" post="Study Group. Hepatology1998;27:1394–402.9581697 [15]ToyodaHKumadaTTadaTet al.Risk factors of hepatocellular carcinoma"/>
 <result pre="interferon treatment in patients with chronic hepatitis C. Osaka Liver" exact="Disease" post="Study Group. Hepatology1998;27:1394–402.9581697 [15]ToyodaHKumadaTTadaTet al.Risk factors of hepatocellular carcinoma"/>
 <result pre="Osaka Liver Disease Study Group. Hepatology1998;27:1394–402.9581697 [15]ToyodaHKumadaTTadaTet al.Risk factors of" exact="hepatocellular carcinoma" post="development in non-cirrhotic patients with sustained virologic response for"/>
 <result pre="Liver Disease Study Group. Hepatology1998;27:1394–402.9581697 [15]ToyodaHKumadaTTadaTet al.Risk factors of hepatocellular" exact="carcinoma" post="development in non-cirrhotic patients with sustained virologic response for"/>
 <result pre="carcinoma development in non-cirrhotic patients with sustained virologic response for" exact="chronic hepatitis" post="C virus infection. J Gastroenterol Hepatol2015;30:1183–9.25678094 [16]MoonCJungKSKim doYet al.Lower"/>
 <result pre="development in non-cirrhotic patients with sustained virologic response for chronic" exact="hepatitis" post="C virus infection. J Gastroenterol Hepatol2015;30:1183–9.25678094 [16]MoonCJungKSKim doYet al.Lower"/>
 <result pre="non-cirrhotic patients with sustained virologic response for chronic hepatitis C" exact="virus infection." post="J Gastroenterol Hepatol2015;30:1183–9.25678094 [16]MoonCJungKSKim doYet al.Lower incidence of hepatocellular"/>
 <result pre="virus infection. J Gastroenterol Hepatol2015;30:1183–9.25678094 [16]MoonCJungKSKim doYet al.Lower incidence of" exact="hepatocellular carcinoma" post="and cirrhosis in hepatitis C patients with sustained virological"/>
 <result pre="infection. J Gastroenterol Hepatol2015;30:1183–9.25678094 [16]MoonCJungKSKim doYet al.Lower incidence of hepatocellular" exact="carcinoma" post="and cirrhosis in hepatitis C patients with sustained virological"/>
 <result pre="Gastroenterol Hepatol2015;30:1183–9.25678094 [16]MoonCJungKSKim doYet al.Lower incidence of hepatocellular carcinoma and" exact="cirrhosis" post="in hepatitis C patients with sustained virological response by"/>
 <result pre="[16]MoonCJungKSKim doYet al.Lower incidence of hepatocellular carcinoma and cirrhosis in" exact="hepatitis" post="C patients with sustained virological response by pegylated interferon"/>
 <result pre="Dis Sci2015;60:573–81.25236421 [17]HondaTIshigamiMMasudaHet al.Effect of peginterferon alfa-2b and ribavirin on" exact="hepatocellular carcinoma" post="prevention in older patients with chronic hepatitis C. J"/>
 <result pre="Sci2015;60:573–81.25236421 [17]HondaTIshigamiMMasudaHet al.Effect of peginterferon alfa-2b and ribavirin on hepatocellular" exact="carcinoma" post="prevention in older patients with chronic hepatitis C. J"/>
 <result pre="and ribavirin on hepatocellular carcinoma prevention in older patients with" exact="chronic hepatitis" post="C. J Gastroenterol Hepatol2015;30:321–8.25091027 [18]LeeSSJeongSHJangESet al.Prospective cohort study on"/>
 <result pre="ribavirin on hepatocellular carcinoma prevention in older patients with chronic" exact="hepatitis" post="C. J Gastroenterol Hepatol2015;30:321–8.25091027 [18]LeeSSJeongSHJangESet al.Prospective cohort study on"/>
 <result pre="Gastroenterol Hepatol2015;30:321–8.25091027 [18]LeeSSJeongSHJangESet al.Prospective cohort study on the outcomes of" exact="hepatitis" post="C virus-related cirrhosis in South Korea. J Gastroenterol Hepatol2015;30:1281–7.25778783"/>
 <result pre="al.Prospective cohort study on the outcomes of hepatitis C virus-related" exact="cirrhosis" post="in South Korea. J Gastroenterol Hepatol2015;30:1281–7.25778783 [19]OgawaEFurusyoNKajiwaraEet al.Efficacy of"/>
 <result pre="pegylated interferon alpha-2b and ribavirin treatment on the risk of" exact="hepatocellular carcinoma" post="in patients with chronic hepatitis C: a prospective, multicenter"/>
 <result pre="interferon alpha-2b and ribavirin treatment on the risk of hepatocellular" exact="carcinoma" post="in patients with chronic hepatitis C: a prospective, multicenter"/>
 <result pre="treatment on the risk of hepatocellular carcinoma in patients with" exact="chronic hepatitis" post="C: a prospective, multicenter study. J Hepatol2013;58:495–501.23099187 [20]Fernandez-RodriguezCMAlonsoSMartinezSMet al.Peginterferon"/>
 <result pre="on the risk of hepatocellular carcinoma in patients with chronic" exact="hepatitis" post="C: a prospective, multicenter study. J Hepatol2013;58:495–501.23099187 [20]Fernandez-RodriguezCMAlonsoSMartinezSMet al.Peginterferon"/>
 <result pre="and ribavirin therapy on hepatocellular carcinoma: incidence and survival in" exact="hepatitis" post="C patients with advanced fibrosis. J Hepatol2010;52:652–7.20346533 [22]BruixJCastellsABoschJet al.Surgical"/>
 <result pre="patients with advanced fibrosis. J Hepatol2010;52:652–7.20346533 [22]BruixJCastellsABoschJet al.Surgical resection of" exact="hepatocellular carcinoma" post="in cirrhotic patients: prognostic value of preoperative portal pressure."/>
 <result pre="with advanced fibrosis. J Hepatol2010;52:652–7.20346533 [22]BruixJCastellsABoschJet al.Surgical resection of hepatocellular" exact="carcinoma" post="in cirrhotic patients: prognostic value of preoperative portal pressure."/>
 <result pre="infection. N Engl J Med2014;370:1889–98.24725239 [25]LawitzEMangiaAWylesDet al.Sofosbuvir for previously untreated" exact="chronic hepatitis" post="C infection. N Engl J Med2013;368:1878–87.23607594 [26]FriedMWSide effects of"/>
 <result pre="N Engl J Med2014;370:1889–98.24725239 [25]LawitzEMangiaAWylesDet al.Sofosbuvir for previously untreated chronic" exact="hepatitis" post="C infection. N Engl J Med2013;368:1878–87.23607594 [26]FriedMWSide effects of"/>
 <result pre="infection. N Engl J Med2013;368:1878–87.23607594 [26]FriedMWSide effects of therapy of" exact="hepatitis" post="C and their management. Hepatology2002;36:S237–44.12407599 [27]RussoMWFriedMWSide effects of therapy"/>
 <result pre="C and their management. Hepatology2002;36:S237–44.12407599 [27]RussoMWFriedMWSide effects of therapy for" exact="chronic hepatitis" post="C. Gastroenterology2003;124:1711–9.12761728 [28]MannsMPolSJacobsonIMet al.All-oral daclatasvir plus asunaprevir for hepatitis"/>
 <result pre="and their management. Hepatology2002;36:S237–44.12407599 [27]RussoMWFriedMWSide effects of therapy for chronic" exact="hepatitis" post="C. Gastroenterology2003;124:1711–9.12761728 [28]MannsMPolSJacobsonIMet al.All-oral daclatasvir plus asunaprevir for hepatitis"/>
 <result pre="chronic hepatitis C. Gastroenterology2003;124:1711–9.12761728 [28]MannsMPolSJacobsonIMet al.All-oral daclatasvir plus asunaprevir for" exact="hepatitis" post="C virus genotype 1b: a multinational, phase 3, multicohort"/>
 <result pre="al.Efficacy of Ledipasvir plus Sofosobuvir with or without ribavirin in" exact="hepatitis" post="C genotype 1 patients who failed previous treatment with"/>
 <result pre="plus ribavirin in patients aged 65 years and older with" exact="chronic hepatitis" post="C. Liver Int2010;30:527–37.19523048 [33]ThabutDLe CalvezSThibaultVet al.Hepatitis C in 6,865"/>
 <result pre="ribavirin in patients aged 65 years and older with chronic" exact="hepatitis" post="C. Liver Int2010;30:527–37.19523048 [33]ThabutDLe CalvezSThibaultVet al.Hepatitis C in 6,865"/>
 <result pre="a severe and neglected curable disease?Am J Gastroenterol2006;101:1260–7.16771947 [34]SaabSRheemJSundaramVHepatitis C" exact="infection" post="in the elderly. Dig Dis Sci2015;60:3170–80.26008618 [35]ModiAANazarioHTrotterJFet al.Safety and"/>
 <result pre="with or without ribavirin in patients with decompensated genotype 1" exact="hepatitis" post="C cirrhosis. Liver Transplant2016;22:281–6. [36]MorenoCLasserLDelwaideJet al.Sofosbuvir in combination with"/>
 <result pre="al.Sofosbuvir in combination with simeprevir +/− ribavirin in genotype 4" exact="hepatitis" post="C patients with advanced fibrosis or cirrhosis: real-life experience"/>
 <result pre="carcinoma: an update. Hepatology2011;53:1020–2.21374666 [38]TerraultNABzowejNHChangKMet al.AASLD guidelines for treatment of" exact="chronic hepatitis" post="B. Hepatology2016;63:261–83.26566064 [39]ContiFBuonfiglioliFScuteriAet al.Early occurrence and recurrence of hepatocellular"/>
 <result pre="an update. Hepatology2011;53:1020–2.21374666 [38]TerraultNABzowejNHChangKMet al.AASLD guidelines for treatment of chronic" exact="hepatitis" post="B. Hepatology2016;63:261–83.26566064 [39]ContiFBuonfiglioliFScuteriAet al.Early occurrence and recurrence of hepatocellular"/>
 <result pre="chronic hepatitis B. Hepatology2016;63:261–83.26566064 [39]ContiFBuonfiglioliFScuteriAet al.Early occurrence and recurrence of" exact="hepatocellular carcinoma" post="in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol2016;65:727–33.27349488"/>
 <result pre="hepatitis B. Hepatology2016;63:261–83.26566064 [39]ContiFBuonfiglioliFScuteriAet al.Early occurrence and recurrence of hepatocellular" exact="carcinoma" post="in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol2016;65:727–33.27349488"/>
 <result pre="[39]ContiFBuonfiglioliFScuteriAet al.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related" exact="cirrhosis" post="treated with direct-acting antivirals. J Hepatol2016;65:727–33.27349488 [40]ReigMMarinoZPerelloCet al.Unexpected high"/>
 <result pre="direct-acting antivirals. J Hepatol2016;65:727–33.27349488 [40]ReigMMarinoZPerelloCet al.Unexpected high rate of early" exact="tumor" post="recurrence in patients with HCV-related HCC undergoing interferon-free therapy."/>
 <result pre="interferon-free therapy. J Hepatol2016;65:719–26.27084592 [41]collab: ANRS Collaborative Study Group on" exact="Hepatocellular" post="Carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT"/>
 <result pre="therapy. J Hepatol2016;65:719–26.27084592 [41]collab: ANRS Collaborative Study Group on Hepatocellular" exact="Carcinoma" post="(ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT Cohorts)Lack"/>
</results>
